NCT06548867View on ClinicalTrials.gov

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.

Trial Locations (1)

42123

RECRUITING

AUSL-IRCCS of Reggio Emilia, Reggio Emilia

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Yghea

UNKNOWN

collaborator

Ipsen

INDUSTRY

lead

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER

NCT06548867 - Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib | Biotech Hunter | Biotech Hunter